Results 171 to 180 of about 100,610 (328)

A century of assessment: A systematic review of biothreat risk assessments

open access: yesRisk Analysis, EarlyView.
Abstract Throughout the past century, assessments of the risks and benefits posed by high‐consequence biological agents have guided US decision‐making on weapons research, countermeasure development, and security policy. However, the dispersed nature of these biothreat risk assessments has presented various difficulties, such as duplicative effort ...
Claire Atkerson, Michael T Parker
wiley   +1 more source

Endoscopic resection of polypoid solitary rectal ulcer: A novel first‐line therapeutic strategy using snare‐assisted mucosal and fibrosis resection

open access: yesDEN Open, Volume 6, Issue 1, April 2026.
Abstract Objectives To propose a novel first‐line endoscopic therapy for treating polypoid lesions in solitary rectal ulcer syndrome (P‐SRUS), the rarest and most challenging subtype of SRUS, which encompasses various endoscopic findings including mucosal erythema, superficial or deep ulcers, and polypoid lesions.
Mojgan Forootan   +12 more
wiley   +1 more source

Botulinum toxin type A for the management of glabellar rhytids

open access: yesClinical, Cosmetic and Investigational Dermatology, 2010
Anne Marie Tremaine, Jerry L McCulloughDepartment of Dermatology, University of California, Irvine, CA, USAAbstract: There is an increasing demand for minimally-invasive cosmetic procedures to arrest the aging process.
Anne Marie Tremaine, Jerry L McCullough
doaj  

Transforming Growth Factor‐Beta Signaling in Cancer: Therapeutic Implications, Challenges, and Pathways to Progress

open access: yesMedComm – Oncology, Volume 4, Issue 3, September 2025.
TGF‐β inhibition is emerging as a promising cancer therapy, yet translating laboratory success to bedside implementation has suffered significant setbacks. The associated challenges include adverse drug reactions, inadequate predictive models, and activation of alternative signaling pathways.
Faizah A. Alabi   +5 more
wiley   +1 more source

Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open‐label study extension of the SALIVA trial

open access: yesDevelopmental Medicine &Child Neurology, Volume 67, Issue 8, Page 1085-1094, August 2025.
Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16268 Abstract Aims To test the long‐term efficacy, safety, and impact on quality of life (QoL) of an oral paediatric formulation of 320 μg/mL glycopyrronium in the 36‐week SALIVA (Sialanar plus orAl rehabiLitation against placebo plus oral rehabilitation for chIldren and ...
Pierre Fayoux   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy